The impacts of total body irradiation on umbilical cord blood hematopoietic stem cell transplantation.

IF 3.4 3区 医学 Q2 HEMATOLOGY Therapeutic Advances in Hematology Pub Date : 2023-01-01 DOI:10.1177/20406207231170708
Hao Wang, Kristin N Berger, Elizabeth L Miller, Wei Fu, Larisa Broglie, Frederick D Goldman, Heiko Konig, Su Jin Lim, Arthur S Berg, Julie-An Talano, Melanie A Comito, Sherif S Farag, Jeffrey J Pu
{"title":"The impacts of total body irradiation on umbilical cord blood hematopoietic stem cell transplantation.","authors":"Hao Wang,&nbsp;Kristin N Berger,&nbsp;Elizabeth L Miller,&nbsp;Wei Fu,&nbsp;Larisa Broglie,&nbsp;Frederick D Goldman,&nbsp;Heiko Konig,&nbsp;Su Jin Lim,&nbsp;Arthur S Berg,&nbsp;Julie-An Talano,&nbsp;Melanie A Comito,&nbsp;Sherif S Farag,&nbsp;Jeffrey J Pu","doi":"10.1177/20406207231170708","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Umbilical cord blood hematopoietic stem cells are commonly used for hematopoietic system reconstitution in recipients after umbilical cord blood transplantation (UCBT). However, the optimal conditioning regimen for UCBT remains a topic of debate. The exact impact of total body irradiation (TBI) as a part of conditioning regimens remains unknown.</p><p><strong>Objectives: </strong>The aim of this study was to evaluate the impacts of TBI on UCBT outcomes.</p><p><strong>Design: </strong>This was a multi-institution retrospective study.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on the outcomes of 136 patients receiving UCBT. Sixty-nine patients received myeloablative conditioning (MAC), in which 33 underwent TBI and 36 did not, and 67 patients received reduced-intensity conditioning (RIC), in which 43 underwent TBI and 24 did not. Univariate and multivariate analyses were conducted to compare the outcomes and the post-transplant complications between patients who did and did not undergo TBI in the MAC subgroup and RIC subgroup, respectively.</p><p><strong>Results: </strong>In the RIC subgroup, patients who underwent TBI had superior overall survival (adjusted hazard ratio [aHR] = 0.25, 95% confidence interval [CI]: 0.09-0.66, p = 0.005) and progression-free survival (aHR = 0.26, 95% CI: 0.10-0.66, p = 0.005). However, in the MAC subgroup, there were no statistically significant differences between those receiving and not receiving TBI.</p><p><strong>Conclusion: </strong>In the setting of RIC in UCBT, TBI utilization can improve overall survival and progression-free survival. However, TBI does not show superiority in the MAC setting.</p>","PeriodicalId":23048,"journal":{"name":"Therapeutic Advances in Hematology","volume":null,"pages":null},"PeriodicalIF":3.4000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/03/0e/10.1177_20406207231170708.PMC10161310.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Hematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/20406207231170708","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Umbilical cord blood hematopoietic stem cells are commonly used for hematopoietic system reconstitution in recipients after umbilical cord blood transplantation (UCBT). However, the optimal conditioning regimen for UCBT remains a topic of debate. The exact impact of total body irradiation (TBI) as a part of conditioning regimens remains unknown.

Objectives: The aim of this study was to evaluate the impacts of TBI on UCBT outcomes.

Design: This was a multi-institution retrospective study.

Methods: A retrospective analysis was conducted on the outcomes of 136 patients receiving UCBT. Sixty-nine patients received myeloablative conditioning (MAC), in which 33 underwent TBI and 36 did not, and 67 patients received reduced-intensity conditioning (RIC), in which 43 underwent TBI and 24 did not. Univariate and multivariate analyses were conducted to compare the outcomes and the post-transplant complications between patients who did and did not undergo TBI in the MAC subgroup and RIC subgroup, respectively.

Results: In the RIC subgroup, patients who underwent TBI had superior overall survival (adjusted hazard ratio [aHR] = 0.25, 95% confidence interval [CI]: 0.09-0.66, p = 0.005) and progression-free survival (aHR = 0.26, 95% CI: 0.10-0.66, p = 0.005). However, in the MAC subgroup, there were no statistically significant differences between those receiving and not receiving TBI.

Conclusion: In the setting of RIC in UCBT, TBI utilization can improve overall survival and progression-free survival. However, TBI does not show superiority in the MAC setting.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
全身照射对脐带血造血干细胞移植的影响。
背景:脐带血造血干细胞常用于脐带血移植(UCBT)后受者的造血系统重建。然而,UCBT的最佳调理方案仍然是一个有争议的话题。作为调理方案的一部分,全身照射(TBI)的确切影响尚不清楚。目的:本研究的目的是评估脑外伤对UCBT结果的影响。设计:这是一项多机构回顾性研究。方法:对136例接受UCBT治疗的患者进行回顾性分析。69例患者接受了清髓调节(MAC),其中33例接受了TBI, 36例未接受TBI; 67例患者接受了降低强度调节(RIC),其中43例接受了TBI, 24例未接受TBI。进行单因素和多因素分析,分别比较MAC亚组和RIC亚组中接受和未接受TBI的患者的结局和移植后并发症。结果:在RIC亚组中,接受TBI的患者总体生存期(校正风险比[aHR] = 0.25, 95%可信区间[CI]: 0.09-0.66, p = 0.005)和无进展生存期(aHR = 0.26, 95% CI: 0.10-0.66, p = 0.005)更优等。然而,在MAC亚组中,接受和未接受TBI的患者之间没有统计学上的显著差异。结论:在UCBT的RIC设置中,TBI的使用可以提高总生存期和无进展生存期。然而,TBI在MAC设置中并没有表现出优势。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
4.30
自引率
0.00%
发文量
54
审稿时长
7 weeks
期刊介绍: Therapeutic Advances in Hematology delivers the highest quality peer-reviewed articles, reviews, and scholarly comment on pioneering efforts and innovative studies across all areas of hematology. The journal has a strong clinical and pharmacological focus and is aimed at clinicians and researchers in hematology, providing a forum in print and online for publishing the highest quality articles in this area.
期刊最新文献
Pharmacokinetics, pharmacodynamics, safety, and efficacy of crizanlizumab in patients with sickle cell disease: final results from the phase II SOLACE-adults study. Long-term risks of cardiovascular-specific mortality among myeloproliferative neoplasms patients. Clinical features and treatment of newly diagnosed multiple myeloma with secondary myelofibrosis: a retrospective study. Real-world efficacy of chidamide plus R-CHOP in newly diagnosed double-expressor diffuse large B-cell lymphoma. Iron deficiency anemia: an early clinical presentation of cytomegalovirus-induced hemorrhagic colitis in chronic myeloid leukemia patients under dasatinib treatment.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1